AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
